Results 261 to 270 of about 2,461,363 (302)
Some of the next articles are maybe not open access.
Antiplatelet therapy in cardiology
Clinical Medicine (Russian Journal), 2016Platelets are important components of hemostasis and play a key role in the formation of atherothrombosis. Rupture or erosion of atherosclerotic plaque gives rise to a thrombus with the involvement of platelets. Antiplatelet agents are instrumental in preventing the development of atherothrombosis of different localization, including coronary arteries.
L V, Popova +2 more
openaire +2 more sources
Platelets are a crucial component in the maintenance of normal haemostasis. In response to vascular damage, activated platelets adhere to the damaged endothelium leading to both aggregation and coagulation. Under healthy conditions, these processes prevent excessive vascular haemorrhage and promote vascular repair and regeneration.
Richard T, Amison, Simon C, Pitchford
openaire +2 more sources
Richard T, Amison, Simon C, Pitchford
openaire +2 more sources
Stents and Antiplatelet Therapy
2012Coronary stents are used during the majority of percutaneous coronary interventions. When compared to medical therapy, they have been shown to decrease mortality for patients with acute coronary syndromes, and to improve symptom control in patients with stable angina.
Amir-Ali, Fassa, Philip, Urban
openaire +2 more sources
Ticlopidine and Antiplatelet Therapy
Annals of Pharmacotherapy, 1993OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of ticlopidine. Comparisons with other antiplatelet agents are presented, with an emphasis on efficacy, and a recommendation is provided regarding ticlopidine's place in therapy.
P, Flores-Runk, R H, Raasch
openaire +2 more sources
Advances in antiplatelet therapy
Expert Opinion on Emerging Drugs, 2003Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in the western world. These disorders share a common pathophysiology -- atherosclerosis, which affects various arterial beds, leading to protean manifestations (coronary artery disease [CAD], stroke, peripheral arterial disease [PAD]).
Hani, Jneid, Deepak L, Bhatt
openaire +2 more sources
Resistance to antiplatelet therapy
Current Cardiology Reports, 2005Cardiovascular mortality continues to be high and events continue to occur in patients taking antiplatelet medications. Aspirin and clopidogrel have become integral parts of management in patients with coronary artery disease and after percutaneous angioplasty. However, the platelet responses to aspirin and clopidogrel are not uniform.
Sasidhar, Guthikonda +2 more
openaire +2 more sources
Monitoring Antiplatelet Therapy
Seminars in Thrombosis and Hemostasis, 2017The increasing use of antiplatelet therapy, particularly aspirin and oral P2Y12 inhibitors, in the prevention and management of arterial thrombosis, has stimulated extensive pharmacodynamic studies and research into tailored antiplatelet regimens. Many different methodologies have been studied for monitoring antiplatelet drugs and some are now well ...
Rachel, Orme +2 more
openaire +2 more sources
Advances in Antiplatelet Therapy
Hematology, 2011Abstract Because of the central role of platelets in cardiovascular atherothrombosis, there is a well-established therapeutic role for antiplatelet therapy that includes aspirin (a cyclooxygenase 1 [COX1] inhibitor), clopidogrel (an antagonist of the ADP P2Y12 receptor), and the GPIIb-GPIIIa (αIIbβ3) antagonists. However, there remains a
openaire +2 more sources
Antiplatelet Therapy in Cerebrovascular Disorders
2012Antiplatelet treatment is a mainstay in acute and long-term secondary stroke prevention. Aspirin is still most widely used worldwide, however, there is increasing evidence from small randomised trials that dual antiplatelet therapy combining aspirin with dipyridamole or clopidogrel might be more effective in the acute and early chronic post-ischemic ...
Weber, Ralph +2 more
openaire +3 more sources